Characteristics of Buserelin-depo use in the treatment for comorbid pathologies of reproductive organs
Khashukoeva A.Z., Agaeva M.I., Agaeva Z.A., Lobacheva Yu.I., Smagina Yu.A.
Proliferative diseases present an important issue in contemporary gynecology. Among gynecological diseases, combinations of benign proliferative diseases represent up to 85% of cases. This pathology is most frequently detected in patients aged 40-45 years. Comorbid proliferative diseases are among the most common indications for radical hysterectomy, a procedure that is complicated by the development of post-hysterectomy syndrome. This condition significantly reduces the quality of life and performance of relatively young women.
The gold standard of therapy for comorbid proliferative disorders is the use of gonadotropin-releasing hormone agonists, which block sex hormone synthesis and have marked antiproliferative, antiangiogenic and anti-inflammatory effects.
This article presents a review of the scientific literature data on the use of the drug Buserelin-depo in the treatment of comorbid proliferative diseases.
Conclusion: According to the literature, the use of Buserelin-depo in the complex therapy for comorbid diseases can lead to a reduction in the size of the enlarged uterus, relatively rapid relief of pain syndrome and abnormal uterine bleeding, reduction in the risk of postoperative complications and recurrences. This significantly improves the quality of life of this group of patients, reduces the number of radical treatments and improves the outcomes of organ-preserving surgeries.
Authors’ contributions: Khashukoeva A.Z., Agaeva M.I., Agaeva Z.A., Lobacheva Yu.I., Smagina Yu.A. – developing the concept and design of the study, obtaining the data for analysis, reviewing publications on the subject of the article, writing the manuscript.
Conflicts of interest: Authors declare lack of the possible conflicts of interests.
Funding: The study was conducted without sponsorship.
For citation: Khashukoeva A.Z., Agaeva M.I., Agaeva Z.A., Lobacheva Yu.I., Smagina Yu.A. Characteristics of Buserelin-depo use in the treatment for comorbid pathologies of reproductive organs.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (3): 200-204 (in Russian)
https://dx.doi.org/10.18565/aig.2025.66
Keywords
Buserelin-depo
gonadotropin-releasing hormone agonists
endometriosis
uterine myoma
endometrial hyperplasia
comorbid pathology
References
- Савельева Г.М., Сухих Г.Т., Серов В.Н, Радзинский В.Е., Манухин И.Б., ред. Национальное руководство. Гинекология. М.: ГЭОТАР-Медиа; 2022. 1008 с. [Savelyeva G.M., Sukhikh G.T., Serov V.N, Radzinsky V.E., Manukhin I.B., ed. National Guide. Gynecology. Moscow: GEOTAR-Media; 2022. 1008 p. (in Russian)].
- Bofill Rodriguez M., Lethaby A., Low C., Cameron I.T. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2019; 8(8): CD001016. https://dx.doi.org/10.1002/14651858.CD001016.pub3.
- Becker C.M., Bokor A., Heikinheimo O., Horne A., Jansen F., Kiesel L. et al.; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum. Reprod. Open. 2022; 2022(2): hoac009. https://dx.doi.org/10.1093/hropen/hoac009.
- Barra F., Grandi G., Tantari M., Scala C., Facchinetti F., Ferrero S. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin. Biol. Ther. 2019; 19(4): 343-60. https://dx.doi.org/10.1080/14712598.2019.1581761.
- Cree I.A., White V.A., Indave B.I., Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020; 76(1): 151-6. https://dx.doi.org/10.1111/his.13977.
- Vercellini P., Bandini V., Buggio L., Barbara G., Berlanda N., Dridi D. et al. Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not? Hum. Reprod. Open. 2023; 2023(2): hoad008. https://dx.doi.org/10.1093/hropen/hoad008.
- Resta C., Moustogiannis A., Chatzinikita E., Ntalianis D.M., Ntalianis K.M., Philippou A. et al. Gonadotropin-releasing hormone (GnRH)/GnRH receptors and their role in the treatment of endometriosis. Cureus. 2023; 15(4): e38136. https://dx.doi.org/10.7759/cureus.38136.
- Surrey E.S. GnRH agonists in the treatment of symptomatic endometriosis: a review. F. S. Rep. 2022; 4(2 Suppl.): 40-5. https://dx.doi.org/10.1016/j.xfre.2022.11.009.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Миома матки. 2020. 48 с. [Ministry of Health of the Russian Federation. Clinical guidelines. Uterine fibroids. 2020. 48 p. (in Russian)].
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. 2022. 42 c. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometriosis. 2022. 42 p. (in Russian)].
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Гиперплазия эндометрия. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometrial hyperplasia. 2024. (in Russian)].
- Management of symptomatic uterine leiomyomas: ACOG Practice Bulletin, Number 228. Obstet Gynecol. 2021 Jun 1;137(6):e100-e115. https://dx.doi.org/10.1097/AOG.0000000000004401.
- Оразов М.Р., Хамошина М.Б., Муллина И.А., Артеменко Ю.С. Гиперплазия эндометрия – от патогенеза к эффективной терапии. Акушерство и гинекология: новости, мнения, обучение. 2021; 9(3): 21-8. [Orazov M.R., Khamoshina M.B., Mullina I.A., Artemenko Yu.S. Endometrial hyperplasia – from pathogenesis to effective therapy. Obstetrics and Gynecology: News, Opinions, Training. 2021; 9(3): 21-8. (in Russian)]. https://dx.doi.org/10.33029/2303-9698-2021-9-3-21-28.
- Gong L., Zhang S., Han Y., Long Q., Zou S., Cao Y. Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial. J. Clin. Pharmacol. 2015; 55(8): 848-53. https://dx.doi.org/10.1002/jcph.485.
- Адамян Л.В., Арсланян К.Н., Харченко Э.И., Логинова О.Н. Современные направления в медикаментозном лечении эндометриоза. Проблемы репродукции. 2019; 25(6): 58-66. [Adamyan L.V., Arslanyan K.N., Kharchenko E.I., Loginova O.N. Modern trends in the treatment of endometriosis. Russian Journal of Human Reproduction. 2019; 25(6): 58-66. (in Russian)]. https://dx.doi.org/10.17116/repro20192506158.
- Рухляда Н.Н., Бирюкова Е.И. Особенности фармакокинетики и биологические эффекты агонистов гонадотропин-рилизинг-гормона. Акушерство и гинекология. 2023; 2: 154-8. [Rukhlyada N.N., Biryukova E.I. The characteristics of pharmacokinetics and the biological effects of gonadotropin-releasing hormone agonists. Obstetrics and Gynecology. 2023; (2): 154-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.42.
- Рухляда Н.Н. Эффективность режима назначения Бусерелина-депо с пролонгированным межинъекционным интервалом: гормональный профиль и приемлемость лечения пациенток с эндометриозом. Акушерство и гинекология. 2023; 10: 153-8. [Rukhliada N.N. The effectiveness of the administration regimen of Buserelin-depo with a prolonged interval between injections: hormonal profile and acceptability of treatment for patients with endometriosis. Obstetrics and Gynecology. 2023; (10): 153-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.245.
- Хашукоева А.З., Агаева М.И., Савченко Т.Н., Агаева З.А., Бурденко М.В., Лобачева Ю.И. Применение Бусерелина-Депо в лечение сочетанной патологии органов репродуктивной системы. Акушерство и гинекология. 2024; 8: 170-4. [Khashukoeva A.Z., Agaeva M.I., Savchenko T.N., Agaeva Z.A., Burdenko M.V., Lobacheva Yu.I. The use of Buserelin-depo in the treatment ofcombined pathology of reproductive organs. Obstetrics and Gynecology. 2024; (8): 170-4 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.180.
- Пустотина О.А. Агонисты гонадотропин-рилизинг гормона и add-back терапия. Российский вестник акушера-гинеколога. 2023; 23(2): 63-9. [Pustotina O.A. Agonists of gonadotropin-releasing-hormone and add-back-therapy. Russian Bulletin of Obstetrician-Gynecologist. 2023; 23(2): 63-9. (in Russian)]. https://dx.doi.org/10.17116/rosakush20232302163.
- Хашукоева А.З., Агаева М.И., Агаева З.А., Савченко Т.Н., Лобачева Ю.И., Губожокова Л.Б., Лукьянова Е.А. Применение Бусерелина-Депо в лечении эндометриоза. Акушерство и гинекология. 2024; 11: 216-20. [Khashukoeva A.Z., Agaeva M.I., Agaeva Z.A., Savchenko T.N., Lobacheva Yu.I., Gubzhokova L.B., Lukyanova E.A. The use of Buserelin-depo in the treatment of endometriosis. Obstetrics and Gynecology. 2024; (11):216-20 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.287.
- Zhang K., Huang S., Xu H., Zhang J., Wang E., Li Y. et al. Effectiveness of gonadotrophin-releasing hormone agonist therapy to improve the outcomes of intrauterine insemination in patients suffering from stage I-II endometriosis. Ann. Med. 2022; 54(1): 1330-8. https://dx.doi.org/10.1080/07853890.2022.2071458.
- Yang Y., Zhu W., Chen S., Zhang G., Chen M., Zhuang Y. Laparoscopic surgery combined with GnRH agonist in endometriosis. J. Coll. Physicians Surg. Pak. 2019; 29(4): 313-6. https://dx.doi.org/10.29271/jcpsp.2019.04.313.
- Щукина Н.А., Буянова С.Н., Бабунашвили Е.Л., Тихомирова Е.В., Земскова Н.Ю., Глебов Т.А. Современные подходы к медикаментозному лечению пациенток с сочетанными пролиферативными заболеваниями матки. Российский вестник акушера-гинеколога. 2022; 22(6): 102-8. [Schukina N.A., Buyanova S.N., Babunashvili E.L., Tikhomirova E.V., Zemskova N.Yu., Glebov T.A. Current approaches to drug therapy in patients with concomitant proliferative uterine diseases. Russian Bulletin of Obstetrician-Gynecologist. 2022; 22(6): 102-8. (in Russian)]. https://doi.org/10.17116/rosakush202222061102.
- Zhang Y., Sun L., Guo Y., Cheng J., Wang Y., Fan S. et al. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: a meta-analysis. Obstet. Gynecol. Surv. 2014; 69(2): 100-8. https://dx.doi.org/10.1097/OGX.0000000000000036.
Received 10.03.2025
Accepted 18.03.2025
About the Authors
Asiyat Z. Khashukoeva, Dr. Med. Sci., Professor, Professor at the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1, +7(916)340-38-13, azk@mail.ru, https://orcid.org/0000-0001-7591-6280Madina I. Agaeva, PhD, Teaching Assistant at the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1, +7(926)081-81-70, madlen1690@mail.ru, https://orcid.org/0000-0001-5138-8357
Zoya A. Agaeva, Dr. Med. Sci., Professor, Senior Lecturer at the Department of Ultrasound and Functional Research Methods, Sklifosovsky Research Institute for Emergency Medicine, 129090, Russia, Moscow, B. Sukharevskaya sqr., 3, +7(952)822-56-56, zoya466@mail.ru, https://orcid.org/0000-0002-2205-0880
Yulia I. Lobacheva, Teaching Assistant at the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1, +7(917)509-08-50, mitu.10@mail.ru, https://orcid.org/0009-0007-9652-3568
Yulia A. Smagina, student, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1,
+7(968)601-67-45, yulia-smagina709@mail.ru, https://orcid.org/0009-0009-3893-4988
Similar Articles
